EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC 4.0

Adjudicating Heart Failure as an End Point in Dialysis Trials: More Signal, Less Noise

Emma O Apos Lone, Patrick B Mark

American Journal of Nephrology · 25.06.2026 · 1-5

DOI: 10.1159/000553102 ↗

Kurz gefasst

Kommentar in der Zeitschrift American Journal of Nephrology, online erschienen am 25.06.2026. Verfasst von Emma O Apos Lone und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersClinical trialsHeart failureHemodialysisNatriuretic peptides

Autor:innen und Institutionen

  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Camperdown, Sydney, New South Wales, Australia.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK, patrick.mark@glasgow.ac.uk.
  • Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK, patrick.mark@glasgow.ac.uk.

Zitieren

APA

O Apos Lone, E., & Mark, P. B. (2026). Adjudicating Heart Failure as an End Point in Dialysis Trials: More Signal, Less Noise. American Journal of Nephrology, 1-5. https://doi.org/10.1159/000553102

Vancouver

O Apos Lone E, Mark PB. Adjudicating Heart Failure as an End Point in Dialysis Trials: More Signal, Less Noise. American Journal of Nephrology. 2026:1-5. doi:10.1159/000553102

BibTeX
@article{OAposLone2026,
  author = {O Apos Lone, Emma and Mark, Patrick B},
  title = {Adjudicating Heart Failure as an End Point in Dialysis Trials: More Signal, Less Noise},
  journal = {American Journal of Nephrology},
  year = {2026},
  pages = {1--5},
  doi = {10.1159/000553102}
}
Kostenlos starten →